Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Tenax Therapeutics, Inc.NASDAQ: TENX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $15.72M (cash outflow) rose 51.0% year over year, ahead of the -78.1% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at +68.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$74.84M (+42.3%) for the fiscal year ending Dec 2026, a slowdown from the +198.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$15.72M-142.4% QoQ
- Last fiscal yearDec 2025
- -$52.6M+198.8% YoY
- LTMMar 2026
- -$5.31M-78.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +51.0% | +64.0% | +13.0 pp |
| 1 year | +198.8% | +42.3% | -156.5 pp |
| 3-year CAGR | +68.2% | +15.9% | -52.4 pp |
| 5-year CAGR | -37.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (52.6M) USD
- Year-over-year change
- -198.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (52.6M) | -198.8% |
| FY2024 | 2024-12-31 | (17.6M) | -128.3% |
| FY2023 | 2023-12-31 | (7.71M) | +30.2% |
| FY2022 | 2022-12-31 | (11.05M) | +66.0% |
| FY2021 | 2021-12-31 | (32.47M) | — |
Net Income vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's LTM Mar 2026 net income of $5.31M is the smallest of the 7 companies compared; the peer median is $45.27M.
- Its year-over-year change of -78.1% is the lowest of 6, against a peer median of -14.8%.
- Over three fiscal years its annual growth of +68.2% compares with a peer median of +1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $108.22B | — | +109.1% | — | |
| LTM Jun 2026 | $71.75M | +93.6% | — | — | |
| LTM Mar 2026 | $55.99M | -14.8% | +8.2% | — | |
| LTM Mar 2026 | $34.55M | -23.8% | -4.9% | — | |
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| LTM Mar 2026 | $17.83M | -73.0% | -9.9% | 48.0% | |
| LTM Mar 2026 | $5.31M | -78.1% | +68.2% | — | |
| Peer median (excluding TENX) | $45.27M | -14.8% | +1.6% | 54.9% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Depreciation & Amortization | 108.98K | 113.33K | 8K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 191K | 1.13M | 0 |
| Change in Working Capital | (610.09K) | (1.45M) | 1.58M | 1.64M | (2.36M) |
| Accounts Receivables | (22.5K) | 0 | (306K) | 58K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | (344.95K) | 1.65M | 1.06M | 2.88M |
| Other Working Capital | (587.59K) | (1.1M) | 237K | 523K | (5.25M) |
| Other Non-Cash Items | 22.12M | 366.86K | 25K | 23K | 19.16M |
| Operating Cash Flow | (10.86M) | (12.01M) | (5.9M) | (14.81M) | (35.8M) |
| Capital Expenditures | (5.25K) | (2.33K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (345.54K) | 0 | 0 | 0 | 0 |
| Sales of Investments | 803.4K | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 3K | 0 | 0 |
| Investing Cash Flow | 452.61K | (2.32K) | 3K | 0 | 0 |
| Debt Repayment | 0 | 624.3K | (624K) | (501K) | 0 |
| Common Stock Issued | 9.19M | 7.93M | 14.19M | 100.37M | 38.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 544.65K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 9.74M | 8.55M | 13.57M | 99.87M | 38.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (666.32K) | (3.46M) | 7.67M | 85.06M | 2.71M |
| Free Cash Flow | (10.86M) | (12.02M) | (5.9M) | (14.81M) | (35.8M) |
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.